Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Ipilimumab biosimilar by CStone Pharmaceuticals for Solid Tumor: Likelihood of Approval
Ipilimumab biosimilar is under clinical development by CStone Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData,...
Data Insights
Ipilimumab biosimilar by Innovent Biologics for Metastatic Biliary Tract Cancer: Likelihood of Approval
Ipilimumab biosimilar is under clinical development by Innovent Biologics and currently in Phase II for Metastatic Biliary Tract Cancer. According...